Brokerages Set InMode Ltd. (NASDAQ:INMD) PT at $16.00

InMode Ltd. (NASDAQ:INMDGet Free Report) has earned a consensus rating of “Hold” from the eight analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $16.00.

A number of research firms have commented on INMD. Barclays set a $19.00 target price on shares of InMode and gave the company an “overweight” rating in a research report on Thursday, May 7th. Robert W. Baird decreased their target price on shares of InMode from $17.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th.

Get Our Latest Analysis on InMode

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Prospect Capital Advisors LLC lifted its position in InMode by 50.6% in the first quarter. Prospect Capital Advisors LLC now owns 313,450 shares of the healthcare company’s stock valued at $4,288,000 after buying an additional 105,250 shares during the last quarter. Janus Henderson Group PLC lifted its position in InMode by 5.0% in the first quarter. Janus Henderson Group PLC now owns 932,132 shares of the healthcare company’s stock valued at $12,752,000 after buying an additional 44,575 shares during the last quarter. Eversept Partners LP lifted its position in InMode by 9.4% in the first quarter. Eversept Partners LP now owns 67,744 shares of the healthcare company’s stock valued at $927,000 after buying an additional 5,806 shares during the last quarter. SummitTX Capital L.P. lifted its position in InMode by 28.4% in the first quarter. SummitTX Capital L.P. now owns 42,914 shares of the healthcare company’s stock valued at $587,000 after buying an additional 9,498 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its position in InMode by 187.0% in the first quarter. Lazard Asset Management LLC now owns 51,530 shares of the healthcare company’s stock valued at $705,000 after buying an additional 33,575 shares during the last quarter. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Trading Down 0.3%

Shares of INMD stock opened at $13.50 on Tuesday. The company’s 50-day moving average price is $13.93 and its 200-day moving average price is $14.18. The stock has a market cap of $855.35 million, a price-to-earnings ratio of 9.93 and a beta of 1.94. InMode has a twelve month low of $12.72 and a twelve month high of $16.74.

InMode (NASDAQ:INMDGet Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.30 by ($0.05). The firm had revenue of $82.02 million for the quarter, compared to analyst estimates of $79.84 million. InMode had a net margin of 23.27% and a return on equity of 13.47%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.31 EPS.

InMode Company Profile

(Get Free Report)

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.

Featured Stories

Analyst Recommendations for InMode (NASDAQ:INMD)

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.